| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/PIN.12546 |
| P698 | PubMed publication ID | 28544031 |
| P50 | author | Shingo Sakashita | Q87756692 |
| Aya Shiba-Ishii | Q88151052 | ||
| P2093 | author name string | Tomoki Nakagawa | |
| Yunjung Kim | |||
| Masayuki Noguchi | |||
| Ryan Edbert Husni | |||
| Tomoyo Takeuchi | |||
| P2860 | cites work | The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2 | Q24323126 |
| UBPY: a growth-regulated human ubiquitin isopeptidase. | Q24336064 | ||
| Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes | Q24645701 | ||
| Gene aberrations for precision medicine against lung adenocarcinoma | Q26749348 | ||
| Small adenocarcinoma of the lung. Histologic characteristics and prognosis | Q28302662 | ||
| International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma | Q28303718 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas | Q33634703 | ||
| An atlas of altered expression of deubiquitinating enzymes in human cancer | Q33808690 | ||
| Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas | Q36014004 | ||
| Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors | Q36200403 | ||
| EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy | Q36758325 | ||
| Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. | Q36938818 | ||
| Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis | Q37101643 | ||
| USP8 is a novel target for overcoming gefitinib resistance in lung cancer | Q37476722 | ||
| Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications | Q37682732 | ||
| Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma | Q37815607 | ||
| Deubiquitinases in cancer: new functions and therapeutic options. | Q37945451 | ||
| 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up | Q38190426 | ||
| Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. | Q38506135 | ||
| EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review | Q38909704 | ||
| Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo | Q40142306 | ||
| Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development | Q40360734 | ||
| Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme | Q41387216 | ||
| Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study | Q45192127 | ||
| The Usp8 deubiquitination enzyme is post-translationally modified by tyrosine and serine phosphorylation | Q45329883 | ||
| Epidermal EGFR controls cutaneous host defense and prevents inflammation | Q47728732 | ||
| The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification | Q47945133 | ||
| Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. | Q51607504 | ||
| 14-3-3-dependent inhibition of the deubiquitinating activity of UBPY and its cancellation in the M phase. | Q53532387 | ||
| Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. | Q54653324 | ||
| Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. | Q54783084 | ||
| P433 | issue | 6 | |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 292-301 | |
| P577 | publication date | 2017-05-19 | |
| P1433 | published in | Pathology International | Q15758750 |
| P1476 | title | Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma | |
| P478 | volume | 67 |
| Q64098664 | Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities? |
| Q91789473 | Down-regulation of USP8 Inhibits Cholangiocarcinoma Cell Proliferation and Invasion |
| Q93127216 | Emerging Role of USP8, HMGA, and Non-Coding RNAs in Pituitary Tumorigenesis |
| Q64898836 | High Expression of Ubiquitin-Specific Protease 8 (USP8) Is Associated with Poor Prognosis in Patients with Cervical Squamous Cell Carcinoma. |
| Q61796276 | Mismatch repair-signature mutations activate gene enhancers across human colorectal cancer epigenomes |
| Q89032142 | Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma |
| Q99410781 | TMEM79/MATTRIN defines a pathway for Frizzled regulation and is required for Xenopus embryogenesis |
Search more.